Characterization of Small Genetic Variants in Breast Cancer Cell Line Under Tamoxifen Therapy

Authors

  • Seyed Taghi Heydari Health Policy Research Center, Institute of Heath, Shiraz University of Medical Sciences, Shiraz, Iran
  • Hamed Kharrati-Koopaee Institute of Biotechnology, Shiraz University, Shiraz, Iran
  • Kamran Bagheri Lankarani Health Policy Research Center, Institute of Heath, Shiraz University of Medical Sciences, Shiraz, Iran
  • Mahnaz Nezamivand-Chegini Institute of Biotechnology, Shiraz University, Shiraz, Iran
  • Hassan Giahi Institute of Biotechnology, Shiraz University, Shiraz, Iran
  • Ali Dehshahri Department of Pharmaceutical Biotechnology, Shiraz University of Medical Science, Shiraz, Iran
  • Fatemeh Sabahi Department of Plant Protection, College of Agriculture, Shiraz University, Shiraz, Iran

DOI:

https://doi.org/10.31661/gmj.v12i.2598

Keywords:

Tamoxifen, Breast Neoplasms, RNA-seq

Abstract

Background: Tamoxifen (TAM) is an effective hormone therapy that reduces the risk of cancer recurrence. According to evidence, TAM contributes to the alterations of genetic variants background and plays a role in the effectiveness of treatments via alteration of the genetic variants. The effects of TAM on genomic features were investigated in the current study by discovering genetic variants and finding the answer to the following question: “Is there any association between the alterations of genetic variants under TAM consumption and an effective treatment process?â€
Materials and Methods: Whole-transcriptome (RNA-seq) dataset from four investigations including 10 TAM-treated samples and 9 untreated samples as the control groups were derived from European Bioinformatics Institute (EBI). Using the process of variants calling, the differential genetic variants between and gene ontology enrichment analysis were detected by CLC Genomics Workbench (12).
Results: Current study reported about 5.8 million genetic variants. The outcomes of the chi-square test showed that distributions of genetic variants between control and treated samples were significant (p<0.05). The genetic variants comparison between the control and TAM-treated samples indicated that there were 67 differential genetic variants. Gene ontology enrichment analysis indicated that differential genetic variants were associated with several tumor suppressors and oncogenes including IL6ST, GEN1, FNTA. HSPA5, NSMCE2, and DDX11.
Conclusion: Most of the candidate genes with different genetic variants had dual roles as oncogenes or tumor suppressors. Therefore, it can be argued that TAM does not play a significant role in an effective treatment through alteration of the genetic variants. In other words, it cannot be concluded that the TAM therapy-resulted alterations of genetic variants play a positive or negative role in the treatment process.

References

Alkabban FM, Ferguson T. Breast Cancer StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022. Akram M, Iqbal M, Daniyal M, Khan AU. Awareness and current knowledge of breast cancer. Biol Res. 2017; 50(1): 1-23. https://doi.org/10.1186/s40659-017-0140-9PMid:28969709 PMCid:PMC5625777 Abo-Touk NA, Sakr HA, & Abd El-Lattef ATIF. Switching to letrozole versus continued tamoxifen therapy in treatment of postmenopausal women with early breast cancer. J Egypt Natl Canc Inst. 2010; 22(1): 79-85. Geisler J, Sasano H, Chen S, Purohit A. Steroid sulfatase inhibitors: promising new tools for breast cancer therapy? J Steroid Biochem Mol Biol. 2011; 125(1-2): 39-45. https://doi.org/10.1016/j.jsbmb.2011.02.002PMid:21356310 AlFakeeh A, Brezden-Masley C. Overcoming endocrine resistance in hormone receptor-positive breast cancer. Curr Oncol. 2018; 25(s1): 18-27. https://doi.org/10.3747/co.25.3752PMid:29910644 PMCid:PMC6001756 Szostakowska M, Trębińska-Stryjewska A, Grzybowska EA, Fabisiewicz A. Resistance to endocrine therapy in breast cancer: molecular mechanisms and future goals. Breast Cancer Res Treat. 2019;173(3): 489-497. https://doi.org/10.1007/s10549-018-5023-4PMid:30382472 PMCid:PMC6394602 Moiseenko F, Volkov N, Bogdanov A, Dubina M, Moiseyenko V. Resistance mechanisms to drug therapy in breast cancer and other solid tumors. An opinion F1000Research. 2017;6:288. https://doi.org/10.12688/f1000research.10992.1PMid:28751966 PMCid:PMC5506585 Bachtiar M, Lee CG. Genetics of population differences in drug response. Curr Genet Med Rep. 2013; 1(3):162-170. https://doi.org/10.1007/s40142-013-0017-3 Kharrati KH, Mohammadabadi MR, Tarang A, Kharrati KM, Esmailizadeh KA. Study of the association between the allelic variations in DGAT1 gene with mastitis in Iranian Holstein cattle. Modern genetic. 2012; 11(2): 14-23. Koopaee HK, Koshkoiyeh AE. (2014) SNPs Genotyping technologies and their applications in farm animals breeding programs. Braz Arch Biol Technol. 2014; 57: 87-95. https://doi.org/10.1590/S1516-89132014000100013 Madian AG, Wheeler HE, Jones RB, Dolan ME. (2012) Relating human genetic variation to variation in drug responses. Trends in Genetics. 2012; 28(10): 487-495. https://doi.org/10.1016/j.tig.2012.06.008PMid:22840197 PMCid:PMC3448823 Esfandiari P, Dadpasand M, Kharrati-Koopaee H, Atashi H, Gharghi A, Niazi A. Bioinformatics, phylogenetic and variant association analysis of Ovocalyxin-32 gene reveals its contribution to egg production traits in native chickens. Anim Gene. 2020; 17:200108. https://doi.org/10.1016/j.angen.2020.200108 White IN, Smith LL. Mechanisms of Tamoxifen-Induced Genotoxicity and Carcinogenicity In Hormonal Carcinogenesis II. Springer, New York, NY. 1996;1: 228-239. https://doi.org/10.1007/978-1-4612-2332-0_26 Brown K. Is tamoxifen a genotoxic carcinogen in women?. Mutagenesis. 2009 ;24(5):391-404. https://doi.org/10.1093/mutage/gep022PMid:19505894 Liapis E, McLuckie K, Lewis P, Farmer P, Brown K. Mutagenicity of tamoxifen induced DNA damage in human endometrial cells and in silico prediction of p53 mutation hotspots. Cancer Res. 2008;68(9): 5596-5596. https://doi.org/10.1093/nar/gkn586PMid:18805907 PMCid:PMC2566887 Emons G, Mustea A, Tempfer C. Tamoxifen and Endometrial Cancer: A Janus-Headed Drug. Cancers (Basel). 2020; 7:12(9):2535. https://doi.org/10.3390/cancers12092535PMid:32906618 PMCid:PMC7564212 Davies R, Oreffo VI, Martin EA, Festing MF, White IN, Smith LL, Styles JA. Tamoxifen causes gene mutations in the livers of lambda/lacI transgenic rats. Cancer research. 1997; 57(7):1288-1293. Lorizio W, Wu AH, Beattie MS, Rugo H, Tchu S, Kerlikowske K, Ziv E. Clinical and biomarker predictors of side effects from tamoxifen. Breast Cancer Res Treat. 2012; 132(3):1107-18. https://doi.org/10.1007/s10549-011-1893-4PMid:22207277 PMCid:PMC3335925 Wardell SE, Norris JD, McDonnell DP. Breast Cancer: Targeting mutant estrogen receptors. Elife. 2019; 8: e44181. https://doi.org/10.7554/eLife.44181PMid:30648967 PMCid:PMC6335051 Pinto N, Dolan ME. Clinically relevant genetic variations in drug metabolizing enzymes. Curr Drug Metab. 2011; 12(5):487-97. https://doi.org/10.2174/138920011795495321PMid:21453273 PMCid:PMC3110519 Kharrati-Koopaee H, Ebrahimie E, Dadpasand M, Niazi A, Esmailizadeh A. Genomic analysis reveals variant association with high altitude adaptation in native chickens. Scientific Rep. 2019; 9(1): 1-22. https://doi.org/10.1038/s41598-019-45661-7PMid:31239472 PMCid:PMC6592930 Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B. (2008) Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat Methods. 2008; 5(7): 621-628. https://doi.org/10.1038/nmeth.1226PMid:18516045 Doan R, Cohen ND, Sawyer J, Ghaffari N, Johnson CD, Dindot SV. Whole-genome sequencing and genetic variant analysis of a Quarter Horse mare. BMC genomics. 2012; 13(1):1-12. https://doi.org/10.1186/1471-2164-13-78PMid:22340285 PMCid:PMC3309927 Almansour NM. Triple-Negative Breast Cancer: A Brief Review About Epidemiology, Risk Factors, Signaling Pathways, Treatment and Role of Artificial Intelligence. Front Mol Biosci. 2022 25; 9:836417. https://doi.org/10.3389/fmolb.2022.836417PMid:35145999 PMCid:PMC8824427 Wu Y, Qian Y, Zhou G, Lv J, Yan Q, Dong X. Effect of GEN1 interference on the chemosensitivity of the breast cancer MCF 7 and SKBR3 cell lines. Oncol lett. 2016; 11(6): 3597-3604. https://doi.org/10.3892/ol.2016.4489PMid:27284361 PMCid:PMC4887781 Turnbull C, Hines S, Renwick A, Hughes D, Pernet D, Elliott A, Rahman N. (2010) Mutation and association analysis of GEN1 in breast cancer susceptibility. Breast Cancer Res Treat. 2010; 124(1): 283-288. https://doi.org/10.1007/s10549-010-0949-1PMid:20512659 PMCid:PMC3632835 Sun L, Zhang Y, Pan Z, Li B, Sun M, Zhang X. (2014) Expression and Localization of GEN1 in Mouse Mammary Epithelial Cells. J Biochem Mol Toxicol. 2014; 28(10): 450-455. https://doi.org/10.1002/jbt.21584PMid:24980922 Chang YW, Tseng CF, Wang MY, Chang WC, Lee CC, Chen LT, Su JL. Deacetylation of HSPA5 by HDAC6 leads to GP78-mediated HSPA5 ubiquitination at K447 and suppresses metastasis of breast cancer. Oncogene. 2016; 35(12):1517-1528. https://doi.org/10.1038/onc.2015.214PMid:26119938 Zoppino FC, Guerrero-Gimenez ME, Castro GN, Ciocca DR. Comprehensive transcriptomic analysis of heat shock proteins in the molecular subtypes of human breast cancer. BMC cancer. 2018;18(1): 1-17. https://doi.org/10.1186/s12885-018-4621-1PMid:29954368 PMCid:PMC6022707 Pond KW, de Renty C, Yagle MK, Ellis NA. Rescue of collapsed replication forks is dependent on NSMCE2 to prevent mitotic DNA damage. PLoS Genet. 2019;15(2): e1007942. https://doi.org/10.1371/journal.pgen.1007942PMid:30735491 PMCid:PMC6383951 Jacome A, Gutierrez-Martinez P, Schiavoni F, Tenaglia E, Martinez P, Rodríguez-Acebes S, Fernandez-Capetillo O. NSMCE 2 suppresses cancer and aging in mice independently of its SUMO ligase activity. EMBO J. 2015; 34(21): 2604-2619. https://doi.org/10.15252/embj.201591829PMid:26443207 PMCid:PMC4641528 Cox DG, Hankinson SE, Hunter DJ. Polymorphisms of the AURKA (STK15/Aurora Kinase) gene and breast cancer risk (United States). Cancer Causes & Control. 2006; 17(1): 81-83. https://doi.org/10.1007/s10552-005-0429-9PMid:16411056 Staff S, Isola J, Jumppanen M, Tanner M. Aurora-A gene is frequently amplified in basal-like breast cancer. Oncol Rep. 2010; 23(2): 307-312. https://doi.org/10.3892/or_00000637 Mahtab M, Boavida A, Santos D, Pisani FM. The Genome Stability Maintenance DNA Helicase DDX11 and Its Role in Cancer. Genes. 2021; 12(3): 395. https://doi.org/10.3390/genes12030395PMid:33802088 PMCid:PMC8000936 Tian J, Fan J, Xu J, Ren T, Guo H, Zhou L. circ FNTA accelerates proliferation and invasion of bladder cancer. Oncol lett. 2020; 19(1): 1017-1023. https://doi.org/10.3892/ol.2019.11150 Masjedi A, Hashemi V, Hojjat-Farsangi M, Ghalamfarsa G, Azizi G, Yousefi M, Jadidi-Niaragh F. (2018) The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer. Biomed Pharmacother. 2018; 108:1415-24. https://doi.org/10.1016/j.biopha.2018.09.177PMid:30372844 Jia S, Zhang B, Liu J, Qin Y, Liang C, Shi S, Yu X. ALDOA functions as an oncogene in the highly metastatic pancreatic cancer. Cancer lett. 2016; 374(1): 127-135. https://doi.org/10.1016/j.canlet.2016.01.054PMid:26854714 Mathe A, Wong-Brown M, Morten B, Forbes JF, Braye SG, Avery-Kiejda KA, Scott RJ. (2015) Novel genes associated with lymph node metastasis in triple negative breast cancer. Scientific Rep. 2015; 5(1): 1-13. https://doi.org/10.1038/srep15832PMid:26537449 PMCid:PMC4633580 Gao SP, Sun HF, Fu WY, Li LD, Zhao Y, Chen MT, Jin W. High expression of COX5B is associated with poor prognosis in breast cancer. Future Oncology. 2017;13(19): 1711-1719. https://doi.org/10.2217/fon-2017-0058PMid:28592145

Downloads

Published

2023-06-26

Issue

Vol. 12 (2023): 2023

Section

Original Article

License

https://creativecommons.org/licenses/by/4.0/